EGFR and non-small cell lung carcinoma: To address this challenge, we conducted high-throughput drug screening using two representative EGFR-mutant NSCLC cell lines—PC9 (EGFR exon 19 ELREA-Del) and NCI-H1975 (EGFR L858R/T790M).